Minimal residual disease (MRD) in Waldenström macroglobulinaemia (WM): Impact on survival outcomes with rituximab-based therapies.

Publication date: October 2019Source: Clinical Lymphoma Myeloma and Leukemia, Volume 19, Issue 10, SupplementAuthor(s): Ruth De Tute, Andrew Rawstron, Shirley D'Sa, Guy Pratt, Laura Clifton-Hadley, Oliver Schofield, Nicholas Counsell, Rebecca Auer, Roger Owen
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research